Well-established industry leader whose oncology expertise and transactions record has led to multiple approved therapeutic ...

A new study found that aged neurons have defects in key proteins that make them vulnerable to molecular stress and neurodegenerative damage.

How does the cell select this information? A large molecular machine called the spliceosome continuously separates the coding and non-coding regions of our genes – and it's doing this even as ...

Akari Therapeutics is an oncology biotechnology company developing next-generation spliceosome payload antibody drug conjugates (ADCs). Utilizing its innovative ADC discovery platform, the Company ...

This and related inhibitors will not only be useful as tools to decipher the roles of the individual components of the spliceosome but may also serve as therapeutics. Using small molecules or ...

As a research associate scientist, he cloned and characterized numerous RNA-RNA interactions of the minor spliceosome. His work was the first to demonstrate the conservation of the minor ...

GenFleet will determine the next steps in development around lymphoma as SELLAS’ focus remains on AML and spliceosome–chromatin mutations, including ASXL1 mutations. PIVOT - Received Preliminary Data ...

The spliceosome modulating properties of spliceostatins and synthetic derivatives opened the door for understanding the underlying spliceosome mechanism as well as the development of new therapies ...